Follow the people · Insider
Peter Blume-Jensen
Peter Blume-Jensen files insider transactions with the SEC as a president and ceo of Acrivon Therapeutics (ACRV). We hold 3 disclosed purchases and sales filed since 16 November 2022, 2 of them in the last 90 days.
- Files forACRV
- Disclosed buys and sells3 in all, 2 in the last 90 days
- Last disclosure27 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 14 November 2022 — 25 August 2026President and CEO · Acrivon Therapeutics (ACRV)42 Form 4 lines · source: SEC Form 4
Everything they disclosed
42 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 14,036 shares of Acrivon TherapeuticsSEC Form 427 August 2026Common Stock · traded 25 August 2026 · filed 27 August 2026
- ▼ sold on the open market 1,229 shares of Acrivon TherapeuticsSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- ▼ sold on the open market 484 shares of Acrivon TherapeuticsSEC Form 420 August 2026Common Stock · traded 18 August 2026 · filed 20 August 2026
- had shares withheld for tax on 13,729 shares of Acrivon TherapeuticsSEC Form 426 May 2026Common Stock · traded 21 May 2026 · filed 26 May 2026
- was granted 180,095 shares of Acrivon TherapeuticsSEC Form 420 May 2026Common Stock · traded 18 May 2026 · filed 20 May 2026
- was granted 72,706 shares of Acrivon TherapeuticsSEC Form 420 May 2026Common Stock · traded 18 May 2026 · filed 20 May 2026
- had shares withheld for tax on 1,253 shares of Acrivon TherapeuticsSEC Form 418 May 2026Common Stock · traded 14 May 2026 · filed 18 May 2026
- had shares withheld for tax on 490 shares of Acrivon TherapeuticsSEC Form 418 May 2026Common Stock · traded 14 May 2026 · filed 18 May 2026
- was granted 417,210 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 1 March 2026 · filed 3 March 2026
- was granted 185,495 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 1 March 2026 · filed 3 March 2026
- was granted 417,210 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 1 March 2026 · filed 3 March 2026
- was granted 185,495 shares of Acrivon Therapeutics (a derivative holding)SEC Form 43 March 2026Stock Option (Right to Buy) · traded 1 March 2026 · filed 3 March 2026
- had shares withheld for tax on 14,265 shares of Acrivon TherapeuticsSEC Form 424 February 2026Common Stock · traded 21 February 2026 · filed 24 February 2026
- had shares withheld for tax on 14,265 shares of Acrivon TherapeuticsSEC Form 424 February 2026Common Stock · traded 21 February 2026 · filed 24 February 2026
- had shares withheld for tax on 1,302 shares of Acrivon TherapeuticsSEC Form 418 February 2026Common Stock · traded 14 February 2026 · filed 18 February 2026
- had shares withheld for tax on 579 shares of Acrivon TherapeuticsSEC Form 418 February 2026Common Stock · traded 14 February 2026 · filed 18 February 2026
- had shares withheld for tax on 1,302 shares of Acrivon TherapeuticsSEC Form 418 February 2026Common Stock · traded 14 February 2026 · filed 18 February 2026
- had shares withheld for tax on 579 shares of Acrivon TherapeuticsSEC Form 418 February 2026Common Stock · traded 14 February 2026 · filed 18 February 2026
- ▲ bought on the open market 49,000 shares of Acrivon TherapeuticsSEC Form 416 January 2026Common Stock · traded 14 January 2026 · filed 16 January 2026
- ▲ bought on the open market 49,000 shares of Acrivon TherapeuticsSEC Form 416 January 2026Common Stock · traded 14 January 2026 · filed 16 January 2026
- had shares withheld for tax on 19,904 shares of Acrivon TherapeuticsSEC Form 423 May 2025Common Stock · traded 21 May 2025 · filed 23 May 2025
- had shares withheld for tax on 59,766 shares of Acrivon TherapeuticsSEC Form 416 May 2025Common Stock · traded 14 May 2025 · filed 16 May 2025
- had shares withheld for tax on 491 shares of Acrivon TherapeuticsSEC Form 416 May 2025Common Stock · traded 14 May 2025 · filed 16 May 2025
- was granted 390,390 shares of Acrivon Therapeutics (a derivative holding)SEC Form 44 March 2025Stock Option (Right to Buy) · traded 1 March 2025 · filed 4 March 2025
- was granted 140,540 shares of Acrivon Therapeutics (a derivative holding)SEC Form 44 March 2025Stock Option (Right to Buy) · traded 1 March 2025 · filed 4 March 2025
- had shares withheld for tax on 19,904 shares of Acrivon TherapeuticsSEC Form 425 February 2025Common Stock · traded 21 February 2025 · filed 25 February 2025
- had shares withheld for tax on 59,766 shares of Acrivon TherapeuticsSEC Form 418 November 2024Common Stock · traded 14 November 2024 · filed 18 November 2024
- had shares withheld for tax on 490 shares of Acrivon TherapeuticsSEC Form 418 November 2024Common Stock · traded 14 November 2024 · filed 18 November 2024
- had shares withheld for tax on 79,616 shares of Acrivon TherapeuticsSEC Form 423 August 2024Common Stock · traded 21 August 2024 · filed 23 August 2024
- had shares withheld for tax on 59,765 shares of Acrivon TherapeuticsSEC Form 416 August 2024Common Stock · traded 14 August 2024 · filed 16 August 2024
- had shares withheld for tax on 54,918 shares of Acrivon TherapeuticsSEC Form 416 May 2024Common Stock · traded 14 May 2024 · filed 16 May 2024
- had shares withheld for tax on 41,861 shares of Acrivon TherapeuticsSEC Form 416 February 2024Common Stock · traded 14 February 2024 · filed 16 February 2024
- had shares withheld for tax on 239,023 shares of Acrivon TherapeuticsSEC Form 416 November 2023Common Stock · traded 14 November 2023 · filed 16 November 2023
- was granted 493,994 shares of Acrivon TherapeuticsSEC Form 423 August 2023Common Stock · traded 21 August 2023 · filed 23 August 2023
- exercised options over 33,605 shares of Acrivon Therapeutics (a derivative holding)SEC Form 41 June 2023Stock Option (Right to Buy) · traded 31 May 2023 · filed 1 June 2023
- exercised options over 33,605 shares of Acrivon TherapeuticsSEC Form 41 June 2023Common Stock · traded 31 May 2023 · filed 1 June 2023
- was granted 180,269 shares of Acrivon Therapeutics (a derivative holding)SEC Form 416 November 2022Stock Option (Right to Buy) · traded 14 November 2022 · filed 16 November 2022
- was granted 80,120 shares of Acrivon Therapeutics (a derivative holding)SEC Form 416 November 2022Stock Option (Right to Buy) · traded 14 November 2022 · filed 16 November 2022
- was granted 934,731 shares of Acrivon TherapeuticsSEC Form 416 November 2022Common Stock · traded 14 November 2022 · filed 16 November 2022
- was granted 503,419 shares of Acrivon TherapeuticsSEC Form 416 November 2022Common Stock · traded 14 November 2022 · filed 16 November 2022
- was granted 60,090 shares of Acrivon TherapeuticsSEC Form 416 November 2022Common Stock · traded 14 November 2022 · filed 16 November 2022
- was granted 26,707 shares of Acrivon TherapeuticsSEC Form 416 November 2022Common Stock · traded 14 November 2022 · filed 16 November 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.